

## Bacterial Resistance Mechanisms: Understanding the threat to global health.

Heike Sharma\*

Department of Biology, Dalhousie University, Canada

### Introduction

Bacterial resistance to antibiotics is one of the most pressing global health challenges today. The evolution of antimicrobial resistance (AMR) has made it increasingly difficult to treat infections that were once easily manageable [1]. What was once seen as a major victory in modern medicine — the discovery of antibiotics — is now threatened by the rapid development of bacterial resistance mechanisms. These mechanisms allow bacteria to survive, reproduce, and thrive despite the presence of antibiotics that would normally kill or inhibit them. Understanding the mechanisms behind bacterial resistance is critical for developing strategies to combat the growing AMR crisis [2].

Bacteria can develop resistance to antibiotics through a variety of mechanisms. These mechanisms can either be innate (naturally occurring) or acquired (through mutations or the transfer of resistance genes). Below are some of the most common ways bacteria resist antibiotics [3]. Many bacteria produce enzymes that can break down or modify antibiotics, rendering them ineffective. This mechanism is particularly common in beta-lactam antibiotics (e.g., penicillin and cephalosporins), which are commonly used to treat bacterial infections. These enzymes degrade the beta-lactam ring, the key structure of beta-lactam antibiotics, and thus inactivate the drug [4]. There are several types of beta-lactamases, including extended-spectrum beta-lactamases (ESBLs) and carbapenemases, which can hydrolyse the extended-spectrum cephalosporins and carbapenems, respectively, making them ineffective [5]. Some bacteria produce enzymes that modify aminoglycosides (such as gentamicin and amikacin) by adding chemical groups to the drug, thereby preventing it from binding to bacterial ribosomes. Bacteria can modify the target site of an antibiotic so that the drug can no longer bind effectively. This is a particularly common mechanism for resistance to antibiotics that interfere with protein synthesis or DNA replication [6, 7].

Several factors contribute to the rise and spread of antibiotic-resistant bacteria. Understanding these factors is crucial for developing strategies to control AMR [8]. The overuse and misuse of antibiotics are major drivers of bacterial resistance. Prescribing antibiotics for viral infections (e.g., the common cold, flu, or viral gastroenteritis) where antibiotics are ineffective. Patients stopping their antibiotic treatment prematurely, before the infection is fully cleared, allowing

surviving bacteria to develop resistance. The routine use of antibiotics in livestock to promote growth and prevent infection has been linked to the development of resistant strains, which can transfer to humans through the food chain. Hospitals and healthcare settings are high-risk environments for the transmission of resistant bacteria due to the heavy use of antibiotics and the concentration of vulnerable patients. Healthcare-associated infections (HAIs), caused by resistant pathogens such as Methicillin-resistant *Staphylococcus aureus* (MRSA) or *Clostridioides difficile*, are a growing concern [9, 10].

### Conclusion

Bacterial resistance mechanisms represent a significant and growing threat to global health, complicating the treatment of infections and leading to longer hospital stays, more expensive treatments, and higher mortality rates. The ability of bacteria to evolve resistance through various mechanisms — from enzymatic degradation to genetic mutation — underscores the importance of taking swift, comprehensive action to address antimicrobial resistance. Through better stewardship of antibiotics, improved infection control measures, the development of new treatments, and global cooperation, we can mitigate the impact of bacterial resistance and protect the effectiveness of antibiotics for future generations. The fight against antimicrobial resistance requires collective action from healthcare providers, policymakers, and the public to ensure that antibiotics remain a powerful tool in the battle against infectious diseases.

### References

1. Ahmad-Mansour N, Loubet P, Pouget C, et al. *Staphylococcus aureus* toxins: an update on their pathogenic properties and potential treatments. *Toxins*. 2021;13(10):677.
2. Loh E, Righetti F, Eichner H, et al. RNA thermometers in bacterial pathogens. *Microbiol Spectr*. 2018;1:55-73.
3. Schröter L, Dersch P. Phenotypic diversification of microbial pathogens—cooperating and preparing for the future. *J Mol Biol*. 2019;431(23):4645-55.
4. Weinert LA, Welch JJ. Why might bacterial pathogens have small genomes?. *Trends Ecol Evol*. 2017;32(12):936-47.

\*Correspondence to: Heike Sharma, Department of Biology, Dalhousie University, Canada, E-mail: heike.sh@gmail.com

Received: 01-Jan-2025, Manuscript No. AAJIDMM-25-161880; Editor assigned: 05-Jan-2025, Pre QC No. AAJIDMM-25-161880 (PQ); Reviewed: 19-Jan-2025, QC No. AAJIDMM-25-161880; Revised: 22-Jan-2025, Manuscript No. AAJIDMM-25-161880 (R); Published: 29-Jan-2025, DOI: 10.35841/aajidmm-9.1.245

5. Sheppard SK. Strain wars and the evolution of opportunistic pathogens. *Curr Opin Microbiol.* 2022;67:102138.
6. Roussin-Léveillé C, Mackey D, Ekanayake G, et al. Extracellular niche establishment by plant pathogens. *Nat Rev Microbiol.* 2024;22(6):360-72.
7. RoyChowdhury M, Sternhagen J, Xin Y, et al. Evolution of pathogenicity in obligate fungal pathogens and allied genera. *PeerJ.* 2022;10:e13794.
8. Banerji R, Kanojiya P, Patil A, et al. Polyamines in the virulence of bacterial pathogens of respiratory tract. *Mol Oral Microbiol.* 2021;36(1):1-1.
9. Saur IM, Hückelhoven R. Recognition and defence of plant-infecting fungal pathogens. *J Plant Physiol.* 2021;256:153324.
10. Leitão JH. Microbial virulence factors. *Int J Mol Sci.* 2020;21(15):5320.